NEW YORK, June 8, 2017 /PRNewswire/ --
DailyStockTracker.com has issued research reports on Gilead
Sciences Inc. (NASDAQ: GILD), Aurinia Pharmaceuticals Inc. (NASDAQ:
AUPH), Esperion Therapeutics Inc. (NASDAQ: ESPR), and Alexion
Pharmaceuticals Inc. (NASDAQ: ALXN). According to Oppenheimer's
Leah Rush Cann, Biotech stocks are trading at a 30%
premium to the market. The group had a price-to-earnings-growth
ratio of 1.86 times versus the S&P 500's PEG ratio 1.43x
through the end of May. Access DailyStockTracker.com's
complimentary reports for today's stocks line-up at:
http://dailystocktracker.com/register/
Gilead Sciences
Shares in Foster City,
California headquartered Gilead Sciences Inc. saw a slight
drop of 0.82%, ending Wednesday's trading session at $64.32. The stock recorded a trading volume of
7.78 million shares. The Company's shares are trading 3.06% below
their 50-day moving average. Moreover, shares of Gilead Sciences,
which discovers, develops, and commercializes medicines in the
areas of unmet medical needs in Europe, North
America, Asia, South America, Africa, Australia, India, and Middle-East, have a Relative Strength Index
(RSI) of 39.29.
On June 01st, 2017,
Gilead Sciences announced that Kevin Young
CBE, COO, and Norbert W.
Bischofberger, PhD, Executive Vice President, R&D and
Chief Scientific Officer, will participate in a fireside chat at
the Goldman Sachs 38th Annual Global Healthcare
Conference on June 15th,
2017, at 10:00 a.m. PT in Ranchos
Palos Verdes, CA. The audio portion of the fireside chat will be
accessible live on the Company's Investors website. Visit us
today and access your complete report on GILD for free at:
http://dailystocktracker.com/registration/?symbol=GILD
Aurinia Pharma
Victoria, Canada headquartered Aurinia Pharmaceuticals
Inc.'s stock declined 2.52%, closing the day at $6.20. A total volume of 1.43 million shares was
traded. The Company's shares have surged 195.24% since the start of
this year. The stock is trading 43.07% above its 200-day moving
average. Additionally, shares of Aurinia Pharma, which engages in
the development of a therapeutic drug to treat autoimmune diseases
in Canada, have an RSI of
37.27.
On May 18th, 2017,
research firm H.C. Wainwright reiterated its 'Buy' rating on the
Company's stock with a decrease of the target price from
$12 a share to $10 a share.
On June 05th, 2017,
Aurinia Pharmaceuticals announced that it presented additional data
from its global Phase IIB AURA-LV study in lupus nephritis during
the 54th European Renal Association-European Dialysis
and Transplant Association Congress in Madrid, Spain. The data were presented on
June 04th, 2017 during the
late-breaking session by lead author James
Tumlin, M.D., a clinical investigator for the study and
founder of Southeast Renal Research Institute. The complimentary
research report on AUPH can be accessed at:
http://dailystocktracker.com/registration/?symbol=AUPH
Esperion Therapeutics
On Wednesday, shares in Ann Arbor,
Michigan headquartered Esperion Therapeutics Inc. (ESPR)
recorded a trading volume of 671,240 shares. The stock ended the
day 0.92% higher at $36.16. The
Company's shares have advanced 4.93% in the past month, 6.29% in
the previous three months, and 188.82% on an YTD basis. The stock
is trading above its 50-day and 200-day moving averages by 1.08%
and 74.95%, respectively. Furthermore, shares of Esperion
Therapeutics, which focuses on developing and commercializing oral
therapies for the treatment of patients with elevated low-density
lipoprotein cholesterol (LDL-C), have an RSI of 57.52.
On May 22nd, 2017, ESPR
provided an update to its shareholders regarding recent trading
activity in its common stock. ESPR wishes to assure its
shareholders, collaboration partners, and colleagues that the
Company remains dedicated to advancing the clinical development of
bempedoic acid for patients with hypercholesterolemia who require
additional LDL-C lowering and for their treating physicians, and to
generating significant long-term value for its shareholders.
Register for free on DailyStockTracker.com and download the
research report on ESPR at:
http://dailystocktracker.com/registration/?symbol=ESPR
Alexion Pharma
New Haven, Connecticut
headquartered Alexion Pharmaceuticals Inc.'s stock dropped 1.31%,
finishing yesterday's session at $100.14. A total volume of 3.06 million shares
was traded, which was above their three months average volume of
2.64 million shares. The Company's shares are trading below their
50-day moving average by 14.15%. Additionally, shares of Alexion
Pharma, which develops and commercializes life-transforming
therapeutic products, have an RSI of 31.60.
On May 25th, 2017,
research firm Morgan Stanley upgraded the Company's stock rating
from 'Equal-Weight' to 'Overweight'.
On May 30th, 2017,
Alexion Pharma announced that management will present at Goldman
Sachs 38th Annual Global Healthcare Conference on
June 13th, 2017, at
2:20 p.m. ET in Rancho Palos Verdes. Management will also
present at the William Blair 37th Annual Growth Stock
Conference on June 14th,
2017, at 12:20 p.m. ET in
Chicago. Get free access to your
research report on ALXN at:
http://dailystocktracker.com/registration/?symbol=ALXN
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. DST has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
DST has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email contact@dailystocktracker.com.
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by DST. DST is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. DST, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, DST, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither DST nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA